Webinar: Key insights on the clinical to commercial transition for autologous therapies

By AmerisourceBergen

The journey from clinical to commercial for vein-to-vein autologous therapies can be challenging and complex

Manufacturers need to understand all of the key aspects of the value chain to ensure an effective transition. 

The journey from clinical to commercial for vein-to-vein autologous therapies can be challenging and complex. Manufacturers need to understand all of the key aspects of the value chain to ensure an effective transition. 

In this webinar, from CAR-TCR 2021, AmerisourceBergen and TrakCel experts share their experiences and discuss how technology advancements, proven solutions and strong partnerships can help deliver an end-to-end solution that is specific to the needs of cell and gene therapy products.